Medical management of Cushing’s disease: what is the future?

Por Fleseriu, Maria, Petersenn, Stephan
Publicado em 2012

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy

Por Fleseriu, Maria, Petersenn, Stephan
Publicado em 2013

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

Por Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Caron, Philippe J.
Publicado no Pituitary (2019)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas

Por Biller, Beverly MK, Colao, Annamaria, Petersenn, Stephan, Bonert, Vivien S, Boscaro, Marco
Publicado em 2010

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Por Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Webb, Susan M.
Publicado no Pituitary (2015)

The Rational Use of Pituitary Stimulation Tests

Por Petersenn, Stephan, Quabbe, Hans-Jürgen, Schöfl, Christof, Stalla, Günter K, von Werder, Klaus, Buchfelder, Michael
Publicado em 2010

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

Por Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Flanagan, Daniel, Tabarin, Antoine, Prévost, Gaëtan, Maisonobe, Pascal, Clermont, Antoine
Publicado em 2014

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

Por Giustina, Andrea, Bronstein, Marcello D., Chanson, Philippe, Petersenn, Stephan, Casanueva, Felipe F., Sert, Caroline, Houchard, Aude, Melmed, Shlomo
Publicado no Pituitary (2019)

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?

Por Petersenn, Stephan, Christ-Crain, Mirjam, Droste, Michael, Finke, Reinhard, Flitsch, Jörg, Kreitschmann-Andermahr, Ilonka, Luger, Anton, Schopohl, Jochen, Stalla, Günter
Publicado no Geburtshilfe Frauenheilkd (2019)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study

Por Findling, James W., Fleseriu, Maria, Newell-Price, John, Petersenn, Stephan, Pivonello, Rosario, Kandra, Albert, Pedroncelli, Alberto M., Biller, Beverly M. K.
Publicado no Endocrine (2016)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease

Por Petersenn, S, Newell-Price, J, Findling, J W, Gu, F, Maldonado, M, Sen, K, Salgado, L R, Colao, A, Biller, B M K
Publicado no Clin Endocrinol (Oxf) (2014)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

Por Petersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., Scaroni, C., Ravichandran, S., Kandra, A., Biller, B. M. K.
Publicado no Endocrine (2017)

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery

Por Petersenn Stephan, Buchfelder Michael, Moche Michael, Tannapfel Andrea, Kluge Regine, Witzigmann Helmut, Lincke Thomas, Fasshauer Mathias, Kratzsch Juergen, Paschke Ralf, Koch Christian A
Publicado em 2006-04-01

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery

Por Fasshauer, Mathias, Lincke, Thomas, Witzigmann, Helmut, Kluge, Regine, Tannapfel, Andrea, Moche, Michael, Buchfelder, Michael, Petersenn, Stephan, Kratzsch, Juergen, Paschke, Ralf, Koch, Christian A
Publicado em 2006

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with...

Por Mercado, Moises, Borges, Fatima, Bouterfa, Hakim, Chang, Tien-Chun, Chervin, Alberto, Farrall, Andrew J, Patocs, Attila, Petersenn, Stephan, Podoba, Jan, Safari, Mitra, Wardlaw, Joanna
Publicado em 2007

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study

Por Giustina, Andrea, Bevan, John S., Bronstein, Marcello D., Casanueva, Felipe F., Chanson, Philippe, Petersenn, Stephan, Thanh, Xuan-Mai Truong, Sert, Caroline, Houchard, Aude, Guillemin, Isabelle, Melmed, Shlomo
Publicado no Pituitary (2015)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

Por Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., Hu, K., Maldonado, M., Biller, B. M. K.
Publicado em 2013

Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications

Por Miermeister, Christian P., Petersenn, Stephan, Buchfelder, Michael, Fahlbusch, Rudolf, Lüdecke, Dieter K., Hölsken, Annett, Bergmann, Markus, Knappe, Hans Ulrich, Hans, Volkmar H., Flitsch, Jörg, Saeger, Wolfgang, Buslei, Rolf
Publicado no Acta Neuropathol Commun (2015)

Erratum: Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications

Por Miermeister, Christian P., Petersenn, Stephan, Buchfelder, Michael, Fahlbusch, Rudolf, Lüdecke, Dieter K., Hölsken, Annett, Bergmann, Markus, Knappe, Ulrich Johannes, Hans, Volkmar H., Flitsch, Jörg, Saeger, Wolfgang, Buslei, Rolf
Publicado no Acta Neuropathol Commun (2016)

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease

Por Newell-Price, John, Pivonello, Rosario, Tabarin, Antoine, Fleseriu, Maria, Witek, Przemysław, Gadelha, Mônica R, Petersenn, Stephan, Tauchmanova, Libuse, Ravichandran, Shoba, Gupta, Pritam, Lacroix, André, Biller, Beverly M K
Publicado no Eur J Endocrinol (2019)